A Randomized Double-Blind Placebo-Controlled Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia

Brief description of study

The purpose of this study is to see how safe and effective an investigational drug called ISIS 678354 is for people with severe hypertriglyceridemia. This drug has not been approved by the United States Food and Drug Administration (FDA) and can only be used for research. The study drug, ISIS 678354, is designed to reduce the amount of apoC-III in the blood. Reducing the amount of apoC-III in the blood may help people lower the amount of triglycerides and chylomicrons (lipoproteins that are largely made of triglycerides) and hopefully reduce some of the symptoms you may experience with high triglyceride levels. This may help lower the risk of developing pancreatitis and to improve other symptoms of severe hypertriglyceridemia. This research study is being conducted to determine the safety, tolerability and efficacy of the study drug, ISIS 678354.


Clinical Study Identifier: s21-01329
ClinicalTrials.gov Identifier: NCT05079919
Principal Investigator: Ira J Goldberg.
Other Investigator: Akankasha Goyal.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.